Dogwood Therapeutics posts Q4 2025 update presentation; no specific data in excerpt

Dogwood Therapeutics, Inc.

Presentation filed as Exhibit 99.1 highlights first-in-class therapies for cancer neuropathy.
No financial results, clinical data, or guidance changes included in the provided excerpt.
Filed as Regulation FD disclosure; presentation may be used with investors and analysts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.